Guardant Health AMEA

Manulife Singapore and Guardant Health announced a joint initiative today, to offer eligible Manulife customers improved access to the Guardant360® liquid biopsy test. This collaboration marks a significant milestone in transforming cancer care in Singapore as it enables access for more Manulife customers with advanced solid tumour cancers to be matched with personalised treatments guided by liquid biopsy, which may help improve clinical outcomes. Read more about the collaboration here: https://lnkd.in/gpcaCAEm

One day to go! Calling All Biopharmaceutical Industry Professionals! Join us on December 5, 2024 from 9am to 9.45am (KST) for a webinar discussion on “Accelerating Clinical Trials with Methylation-based ctDNA Detection for Response Monitoring”. Register for this webinar here: https://lnkd.in/gpN8_Nts This webinar will feature Carin E., Director, Global Scientific Affairs in Guardant Health and Michelle Lee, Associate Director, BioPharma Business Development in Guardant Health. We look forward to your participation. Email us at [email protected] to register for this webinar. To find out more about biopharma solutions offered by Guardant Health, visit us at https://lnkd.in/gTvtVAJX. Visit us at https://lnkd.in/fyqKfNs to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #webinar #biopharma #guardantinfinity #genomics #epigenomics #liquidbiopsy #liquidissolid #clinicaltrials #molecularresponse #responsemonitoring #methylation #ctDNA #drugdevelopment #precisiononcology #nextgenerationsequencing #NGS #comprehensivegenomicprofiling

Check out these 13 abstracts by Guardant Health which will be presented at the European Society for Medical Oncology (ESMO) ASIA Congress 2024 in Suntec Singapore Convention & Exhibition Centre from December 6th to 8th, 2024. https://lnkd.in/gWRqJrZn The ESMO Asia Congress is an annual congress specifically focused on multidisciplinary oncology in the Asian region which provides a platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field. https://lnkd.in/gS2MDADz Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. #guardanthealth #guardanthealthamea #ESMOASIA24 #ESMO24 #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists

Check out this one-minute video which captures fond memories from a joint CSR initiative by Guardant Health AMEA and Singapore Cancer Society (SCS). https://lnkd.in/g7tFw72U On 16 November 2024, as part of our corporate social responsibility (CSR) programmes this year, the Guardant team had the wonderful opportunity to bring SCS beneficiaries which included cancer survivors and their loved ones on a visit to one of Singapore’s favourite tourist attractions, Gardens by the Bay. We visited the Cloud Forest with its grand waterfall and the Flower Dome which was showcasing a colourful flowers exhibition from around the world. The lovely Saturday afternoon ended with a lunch buffet. Thank you Singapore Cancer Society for partnering with us and creating lasting memories with these cancer survivors and their families. At Guardant Health, we believe in putting patients first. With an excellent turnout of 104 participants, Guardant by the Bay 2024 was a roaring success and the Guardant team is grateful for being given an opportunity to serve these patients with cancer and their family members. The smiles from the patients and their loved ones brought everyone closer together, reaffirming that we are all together in this fight against cancer. #guardanthealth #guardanthealthamea #singaporecancersociety #SCS #corporatesocialresponsibility #CSR #creatingmemories #cancerpatients #puttingpatientsfirst

Plasma-based next-generation sequencing (NGS) has demonstrated the potential to guide the personalized treatment of non-small cell lung cancer (NSCLC). However, the published mutational genomic data of NSCLC has largely focused on Western populations. In this study, the investigators retrospectively analyzed results from comprehensive NGS of plasma from patients with advanced non-squamous NSCLC using the Guardant360® test, as seen in clinical practice in Hong Kong, Korea, Taiwan, Japan, and Southeast Asia.¹ https://lnkd.in/g8hXGyFZ Of the 1,608 tested samples, 1,360 (85.6%) had detectable ctDNA. Of these samples where ctDNA was detected, 68.3% had alterations in at least one NCCN-recommended NSCLC biomarker. EGFR driver mutations were most frequent (48.6%), followed by alterations of KRAS (7.9%), ERBB2 (4.1%), and ALK (2.5%).¹ The study findings showed that comprehensive plasma-based NGS provided timely and clinically informative mutational genomic profiling of advanced non-squamous NSCLC in East Asian patients.¹ The ability of Guardant Health’s comprehensive liquid biopsy to detect alterations in patients with advanced-stage non-small cell lung cancer is one of many factors that make our liquid biopsy solid.  Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests, which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: 1. Cho BC, Loong HHF, Tsai C-M, et. al. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. Current Oncology. 2022; 29(3):2154-2164. https://lnkd.in/ga8ADYT3 #guardanthealth #guardanthealthamea #liquidbiopsy #liquidissolid #lungcancer #NSCLC #comprehensivegenomicprofiling #nextgenerationsequencing #NGS #cancerpatients #medicaloncologists

Calling All Biopharmaceutical Industry Professionals! Join us on December 5, 2024 from 9am to 9.45am (KST) for a webinar discussion on “Accelerating Clinical Trials with Methylation-based ctDNA Detection for Response Monitoring”. Register for this webinar here: https://lnkd.in/gpN8_Nts This webinar will feature Carin E., Director, Global Scientific Affairs in Guardant Health and Michelle Lee, Associate Director, BioPharma Business Development in Guardant Health. We look forward to your participation. Email us at [email protected] to register for this webinar. To find out more about biopharma solutions offered by Guardant Health, visit us at https://lnkd.in/gTvtVAJX. Visit us at https://lnkd.in/fyqKfNs to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #webinar #biopharma #guardantinfinity #genomics #epigenomics #liquidbiopsy #liquidissolid #clinicaltrials #molecularresponse #responsemonitoring #methylation #ctDNA #drugdevelopment #precisiononcology #nextgenerationsequencing #NGS #comprehensivegenomicprofiling

Check out this newly published biopharma whitepaper from Citeline: "Precision Oncology Drug Development in China: Opportunities, Challenges, and Fast Paths Forward". Download the whitepaper here: https://lnkd.in/g5AfbRV5 Unlocking the potential of China’s biopharmaceutical market is essential in developing new cancer therapies using comprehensive genomic profiling tests. Guardant Health AMEA is breaking boundaries by enabling local and multinational biopharmaceutical companies in China to grow globally by accelerating oncology clinical research and trial enrolment. This whitepaper delves into the opportunities and challenges faced by China’s biopharmas and global biopharmas as well as fast paths forward in the field of precision oncology drug development in China. Contact our biopharma team at [email protected] to see how we can help you accelerate oncology clinical trials and bring the next generation of cancer therapies to patients sooner . Visit us at https://lnkd.in/gTvtVAJX to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #whitepaper #citeline #biopharma #CDx #companiondiagnostics #drugdevelopment #clinicaltrials #precisiononcology #oncologytrials #china #precisionmedicine #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

One day to go! Calling all oncologists! Join us on November 6th from 7.30pm to 9.00pm (IST) for a webinar discussion entitled “MRD Roundtable: Enhancing patient outcomes through minimal residual disease detection and surveillance monitoring”. Register for this webinar today at https://lnkd.in/gSzzaYy7 This webinar will feature leading medical oncologists from all over India. The chairperson of the session will be Dr. Shekhar Patil from HCG Cancer Centre in Bangalore and the speaker for this session is Dr. Viraj Lavingia from Shalby Hospital in Ahmedabad. This webinar will be moderated by Dr. Amit Rauthan from Manipal Hospital in Bangalore. The panellists of this webinar session include Dr. Sai Vivek Velkuru from Aster Hospital in Bangalore, Dr. Aparna Dhar from Max Super Speciality Hospital in New Delhi, Dr. Palanki Satya Dattatreya from Renova Soumya Cancer Centre in Hyderabad, Dr. Rejiv Rajendranath from Apollo Hospital in Chennai and Dr. Rajat Bajaj from Fortis Hospital in Noida. We look forward to your participation in this webinar. Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. #guardanthealth #guardanthealthamea #webinar #MRD #minimalresidualdisease #surveillancemonitoring #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

November is Lung Cancer Awareness Month. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases worldwide.¹ The current and emerging National Comprehensive Cancer Network (NCCN) guideline-recommended somatic biomarkers for patients with metastatic non-small cell lung cancer include ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1, NTRK2, NTRK3, RET, ROS1.² The expanded panel of the Guardant360® liquid biopsy test with 739 genes can test for all these biomarkers simultaneously. For a patient with advanced stage cancer whose tissue biopsy is insufficient for genetic testing or a patient who wants to identify targeted therapy options while avoiding an invasive repeat tissue biopsy, liquid biopsies are a viable option to detect genomic alterations and match them to appropriate precision medicine and targeted therapy options. Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. Reference: 1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://lnkd.in/dbFemzCM, accessed [14 October 2024]. 2. NCCN Guidelines on Non-Small Cell Lung Cancer Version 4. 2024. https://lnkd.in/gYpXxu6Q. Accessed on October 15, 2024 #guardanthealth #guardanthealthamea #lungcancer #lungcancerawarenessmonth #NSCLC #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists

Calling all oncologists! Join us on November 6th from 7.30pm to 9.00pm (IST) for a webinar discussion entitled “MRD Roundtable: Enhancing patient outcomes through minimal residual disease detection and surveillance monitoring”. Register for this webinar today at https://lnkd.in/gSzzaYy7 This webinar will feature leading medical oncologists from all over India. The chairperson of the session will be Dr. Shekhar Patil from HCG Cancer Centre in Bangalore and the speaker for this session is Dr. Viraj Lavingia from Shalby Hospital in Ahmedabad. This webinar will be moderated by Dr. Amit Rauthan from Manipal Hospital in Bangalore. The panellists of this webinar session include Dr. Sai Vivek Velkuru from Aster Hospital in Bangalore, Dr. Aparna Dhar from Max Super Speciality Hospital in New Delhi, Dr. Palanki Satya Dattatreya from Renova Soumya Cancer Centre in Hyderabad, Dr. Rejiv Rajendranath from Apollo Hospital in Chennai and Dr. Rajat Bajaj from Fortis Hospital in Noida. We look forward to your participation in this webinar. Speak to your doctor today about minimal residual disease (MRD) testing with a simple blood draw. Visit us at https://lnkd.in/dVEkKyRC to find out more about our MRD test which can help oncologists identify patients at a higher risk of recurrence. This test is for prescription use only. #guardanthealth #guardanthealthamea #webinar #MRD #minimalresidualdisease #surveillancemonitoring #precisiononcology #liquidbiopsy #liquidissolid #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #cancerpatients #medicaloncologists